These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 27542322)

  • 1. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
    Sperl J; Horvath G; Halota W; Ruiz-Tapiador JA; Streinu-Cercel A; Jancoriene L; Werling K; Kileng H; Koklu S; Gerstoft J; Urbanek P; Flisiak R; Leiva R; Kazenaite E; Prinzing R; Patel S; Qiu J; Asante-Appiah E; Wahl J; Nguyen BY; Barr E; Platt HL
    J Hepatol; 2016 Dec; 65(6):1112-1119. PubMed ID: 27542322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
    Foster GR; Agarwal K; Cramp ME; Moreea S; Barclay S; Collier J; Brown AS; Ryder SD; Ustianowski A; Forton DM; Fox R; Gordon F; Rosenberg WM; Mutimer DJ; Du J; Gilbert CL; Asante-Appiah E; Wahl J; Robertson MN; Barr E; Haber B
    Hepatology; 2018 Jun; 67(6):2113-2126. PubMed ID: 29473975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection.
    Corman S; Elbasha EH; Michalopoulos SN; Nwankwo C
    Value Health; 2017 Sep; 20(8):1110-1120. PubMed ID: 28964443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
    Lawitz E; Gane E; Pearlman B; Tam E; Ghesquiere W; Guyader D; Alric L; Bronowicki JP; Lester L; Sievert W; Ghalib R; Balart L; Sund F; Lagging M; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
    Lancet; 2015 Mar; 385(9973):1075-86. PubMed ID: 25467591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
    Brown A; Hézode C; Zuckerman E; Foster GR; Zekry A; Roberts SK; Lahser F; Durkan C; Badshah C; Zhang B; Robertson M; Wahl J; Barr E; Haber B;
    J Viral Hepat; 2018 May; 25(5):457-464. PubMed ID: 29152828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
    Gane E; Nahass R; Luketic V; Asante-Appiah E; Hwang P; Robertson M; Wahl J; Barr E; Haber B
    J Viral Hepat; 2017 Oct; 24(10):895-899. PubMed ID: 28470815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
    Sulkowski MS; Moon JS; Sherman KE; Morelli G; Darling JM; Muir AJ; Khalili M; Fishbein DA; Hinestrosa F; Shiffman ML; Di Bisceglie A; Rajender Reddy K; Pearlman B; Lok AS; Fried MW; Stewart PW; Peter J; Wadsworth S; Kixmiller S; Sloan A; Vainorius M; Horne PM; Michael L; Dong M; Evon DM; Segal JB; Nelson DR;
    Hepatology; 2021 Dec; 74(6):2952-2964. PubMed ID: 34255381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
    Kwo P; Gane EJ; Peng CY; Pearlman B; Vierling JM; Serfaty L; Buti M; Shafran S; Stryszak P; Lin L; Gress J; Black S; Dutko FJ; Robertson M; Wahl J; Lupinacci L; Barr E; Haber B
    Gastroenterology; 2017 Jan; 152(1):164-175.e4. PubMed ID: 27720838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
    Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
    Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.
    Zamor PJ; Vierling J; Ghalib R; Luketic V; Ravendhran N; Balart L; Robertson M; Hwang P; Hanna GJ; Nguyen BY; Barr E; Talwani R; Pearlman B
    Am J Gastroenterol; 2018 Jun; 113(6):863-871. PubMed ID: 29695828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
    Kumada H; Suzuki Y; Karino Y; Chayama K; Kawada N; Okanoue T; Itoh Y; Mochida S; Toyoda H; Yoshiji H; Takaki S; Yatsuzuka N; Yodoya E; Iwasa T; Fujimoto G; Robertson MN; Black S; Caro L; Wahl J
    J Gastroenterol; 2017 Apr; 52(4):520-533. PubMed ID: 27873094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review.
    Liu J; Guo M; Ke L; You R
    Front Public Health; 2022; 10():836986. PubMed ID: 35646774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
    Lawitz E; Poordad F; Gutierrez JA; Wells JT; Landaverde CE; Evans B; Howe A; Huang HC; Li JJ; Hwang P; Dutko FJ; Robertson M; Wahl J; Barr E; Haber B
    Hepatology; 2017 Feb; 65(2):439-450. PubMed ID: 27770561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial.
    Yakoot M; Abdo AM; Abdel-Rehim S; Helmy S
    EBioMedicine; 2017 Jul; 21():182-187. PubMed ID: 28647541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
    Gane EJ; Pianko S; Roberts SK; Thompson AJ; Zeuzem S; Zuckerman E; Ben-Ari Z; Foster GR; Agarwal K; Laursen AL; Gerstoft J; Gao W; Huang HC; Fitzgerald B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Zeng Z; Chen HL; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Esteban R
    Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):805-813. PubMed ID: 28802816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
    Papaluca T; Sinclair M; Gow P; Pianko S; Sievert W; Arachchi N; Cameron K; Bowden S; O'Keefe J; Doyle J; Stoove M; Hellard M; Iser D; Thompson A
    Liver Int; 2019 Dec; 39(12):2285-2290. PubMed ID: 31355968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.
    Elbasha EH; Robertson MN; Nwankwo C
    Aliment Pharmacol Ther; 2017 Feb; 45(3):455-467. PubMed ID: 27910116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    Elbasha E; Greaves W; Roth D; Nwankwo C
    J Viral Hepat; 2017 Apr; 24(4):268-279. PubMed ID: 27966249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort.
    Hernández-Conde M; Fernández I; Perelló C; Gallego A; Bonacci M; Pascasio JM; Romero-Gómez M; Llerena S; Fernández-Rodríguez C; Castro Urda JL; García Buey L; Carmona I; Morillas RM; García ND; Gea F; Carrión JA; Castellote J; Moreno-Planas JM; Piqueras Alcol B; Molina E; Diago M; Montoliu S; de la Vega J; Menéndez F; Sánchez Ruano JJ; García-Samaniego J; Rosales-Zabal JM; Anton MD; Badia E; Souto-Rodríguez R; Salmeron FJ; Fernández-Bermejo M; Figueruela B; Moreno-Palomares JJ; Calleja JL
    J Viral Hepat; 2019 Jan; 26(1):55-64. PubMed ID: 30265418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.